PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives

Prostate cancer (PC) is the second most common cancer among men, with 1.3 million yearly cases worldwide. Among those cancer-afflicted men, 30% will develop metastases and some will progress into metastatic castration-resistant prostate cancer (mCRPC), which is associated with a poor prognosis and m...

Full description

Bibliographic Details
Main Authors:	Mohamed El Fakiri, Nicolas M. Geis, Nawal Ayada, Matthias Eder, Ann-Christin Eder
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	Cancers
Subjects:	PSMA prostate-specific membrane antigen targeted radionuclide therapy prostate cancer theranostics
Online Access:	https://www.mdpi.com/2072-6694/13/16/3967

Similar Items

[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)

Surface Modification of Liposomes by a Lipopolymer Targeting Prostate Specific Membrane Antigen for Theranostic Delivery in Prostate Cancer
by: Hooman Yari, et al.
Published: (2019-03-01)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
by: Eline A.M. Ruigrok, et al.
Published: (2019-10-01)

Metal-Based PSMA Radioligands
by: Eleni Gourni, et al.
Published: (2017-03-01)

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy
by: Wallace Jones, et al.
Published: (2020-05-01)

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
by: Thomas S. C. Ng, et al.
Published: (2021-07-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Application of PSMA PET/CT Specific Molecular Imaging in Diagnosis of Non-prostate Cancer
by: LIU Teli, et al.
Published: (2019-11-01)

Solitary castrate-resistant prostate cancer metastasis to adrenal gland with concordant intense avidity on PSMA and FDG PET
by: Stephen McGeorge, et al.
Published: (2021-09-01)

Editor’s Pick: PSMA-Specific Ligands in Prostate Cancer Diagnosis and Therapy
by: Wei Jin, et al.
Published: (2016-04-01)

Theranostics in Oncology—Thriving, Now More than Ever
by: Rudolf A. Werner, et al.
Published: (2021-04-01)

Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer
by: Spencer T. Lake, et al.
Published: (2017-09-01)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
by: Ayman Abouzayed, et al.
Published: (2019-07-01)

PSMA Theranostics: Current Landscape and Future Outlook
by: Hanbo Zhang, et al.
Published: (2021-08-01)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
by: Katharina Kessel, et al.
Published: (2021-07-01)

More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond
by: Anniina Hyväkkä, et al.
Published: (2021-05-01)

Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov
by: Claus Zippel, et al.
Published: (2020-01-01)

PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging
by: Adrien Holzgreve, et al.
Published: (2021-03-01)

Efficacy and safety of 177Lutetium-prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer patients: First experience in West Asia – A prospective study
by: Ramin Akbarian Aghdam, et al.
Published: (2019-01-01)

Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)
by: Maria Luisa Belli, et al.
Published: (2020-11-01)

Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
by: Nat P. Lenzo, et al.
Published: (2018-02-01)

Patient-Reported and Oncological Outcomes of Salvage Therapies for PSMA-Positive Nodal Recurrent Prostate Cancer: Real-Life Experiences and Implications for Future Trial Design
by: Alexander Kretschmer, et al.
Published: (2021-06-01)

A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy
by: Yutong Xing, et al.
Published: (2021-05-01)

Targeted Prostate Biopsy Using 68Gallium PSMA-PET/CT for Image Guidance
by: Demetrios N. Simopoulos, et al.
Published: (2017-09-01)

High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation
by: Labib Ataur Rahman, et al.
Published: (2019-12-01)

PSMA Theranostics: Science and Practice
by: Kgomotso Mokoala, et al.
Published: (2021-08-01)

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
by: Asta Juzeniene, et al.
Published: (2021-02-01)

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative 68Ga-PSMA-11 PET/CT
by: Xuefeng Qiu, et al.
Published: (2021-09-01)

Biomarkers in Prostate-Specific Membrane Antigen Theranostics
by: Panagiotis J. Vlachostergios, et al.
Published: (2021-06-01)

[<sup>177</sup>Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative <i>In Vitro</i> Autoradiography
by: Roswitha Tönnesmann, et al.
Published: (2019-01-01)

Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep
by: Benjamin Baur, et al.
Published: (2014-04-01)

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
by: Philipp E. Hartrampf, et al.
Published: (2020-05-01)

Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
by: Batool Albalooshi, et al.
Published: (2020-01-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
by: Romain Schollhammer, et al.
Published: (2019-06-01)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
by: Eugene Shenderov, et al.
Published: (2018-03-01)

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
by: Alessia Cimadamore, et al.
Published: (2018-12-01)

Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada
by: Sympascho Young, et al.
Published: (2021-08-01)

PSMA-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer
by: Walker, Natalie
Published: (2019)

Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT
by: Steffen Bayerschmidt, et al.
Published: (2021-06-01)